Get the Stockscreener App
36.13
0.64%
0.23
After Hours:
36.13
Indivior Pharmaceuticals Inc stock is traded at $36.13, with a volume of 1.59M.
It is up +0.64% in the last 24 hours and up +3.41% over the past month.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
See More
Previous Close:
$35.90
Open:
$35.58
24h Volume:
1.59M
Relative Volume:
0.85
Market Cap:
$4.26B
Revenue:
$1.29B
Net Income/Loss:
$251.00M
P/E Ratio:
18.30
EPS:
1.9744
Net Cash Flow:
$-193.86M
1W Performance:
+0.78%
1M Performance:
+3.41%
6M Performance:
+18.58%
1Y Performance:
+52.32%
1-Day Range:
$35.58
$36.30
1-Week Range:
$35.03
$36.30
52-Week Range:
$22.95
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
36.13 | 4.23B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
18.37 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.18 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.02 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.55 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
545.00 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Three parties report a passive holding above 5% in Indivior (INDV). - Stock Titan
Indivior stock: company declares conditional USD 8.13 special dividend - AD HOC NEWS
Indivior Pharmaceuticals, Inc. (INDV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - Yahoo Finance
Indivior stock gains 2.96 percent on USD 8.13 dividend plan - AD HOC NEWS
Indivior stock last trades at USD 36.88 on September 28, 2026 - AD HOC NEWS
Legend's five-year data suggests Carvykti could be a cure; Addex and Indivior split up - Endpoints News
Indivior stock at USD 35.82 on September 25, 2026 - AD HOC NEWS
Addex rises as it regains GABAB portfolio from Indivior - The Pharma Letter
Indivior stock carries a USD 8.13 special dividend - AD HOC NEWS
A research partnership ends, returning a substance-use drug candidate to Addex (ADXN). - Stock Titan
Indivior stock heads into the open after a 0.14 percent fall - AD HOC NEWS
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior - marketscreener.com
Indivior stock heads into the open after a 0.77 percent drop - AD HOC NEWS
Indivior Pharmaceuticals stock reports USD 8.13 special dividend - AD HOC NEWS
Layoff Tracker: Novo workforce down 13,000 - BioSpace
Supernus, Indivior get early termination of US waiting period - MLex
Indivior stock holds steady as investors watch fundamentals and momentum - AD HOC NEWS
Indivior Pharmaceuticals Inc (INDV) Stock Up 3.9% but GF Value S - GuruFocus
Indivior stock gains on $8.13 special dividend - AD HOC NEWS
Indivior (NASDAQ: INDV) Announces Conditional $8.13 Special Dividend Pending Merger Completion - Kalkine Media
Indivior declares $8.13 special dividend contingent on merger By Investing.com - Investing.com Nigeria
Form 8K Indivior PLC For: 17 September By Investing.com - Investing.com Australia
Indivior Declares $8.13 Per Share Special Dividend Tied to Supernus Merger Closing - Minichart
Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger - Yahoo Finance
Indivior Declares $8.13 Special Cash Dividend Tied to Supernus Merger - TradingView
An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
Indivior declares $8.13 special dividend contingent on merger - Investing.com
Indivior stock heads into the open after a 0.7% Nasdaq drop - AD HOC NEWS
Understanding Opioid Use Disorder: A Treatable Brain Disease - Indivior
Indivior Accelerates Termination of Suboxone Supply Agreement with Reckitt Benckiser - Kalkine Media
Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January - Investing.com Canada
Form 8K Indivior PLC For: 15 September By Investing.com - Investing.com Nigeria
Indivior PharmaceuticalsCopacker Supply Ag - Moomoo
Indivior Pharmaceuticals, Inc. SEC Filing (Sep 14, 2026) - Stock Titan
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Indivior stock gains as Supernus merger and special dividend plan come into focus - AD HOC NEWS
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion - TradingView
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance - AD HOC NEWS
Indivior stock gains on raised 2026 outlook and strong Sublocade growth - AD HOC NEWS
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Price to earnings forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indiv - The National Law Review
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Indivior stock trades below fair value as latest earnings beat expectations - AD HOC NEWS
Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight - sahmcapital.com
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Indivior Pharmaceuticals Inc Stock (INDV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Anderson Woodrow D | Chief Accounting Officer |
Aug 05 '26 |
Buy |
36.28 |
1,500 |
54,420 |
26,138 |
| Heidbreder Christian | Chief Scientific Officer |
Jul 10 '26 |
Sale |
41.14 |
18,586 |
764,628 |
209,337 |
0.49%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):